Deciphera Pharmaceuticals (DCPH) Osake Kurssi
Deciphera Pharmaceuticals Kurssi
Viimeisten 4 vuoden aikana Deciphera Pharmaceuticalsn liikevaihto kasvoi 59,9 % vuodessa ja ylsi 163,36 M USD:een. Deciphera Pharmaceuticalsn nettomarginaali −119,3 % on noussut verrattuna −766,0 %:iin muutama vuosi sitten.
Deciphera Pharmaceuticals osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Deciphera Pharmaceuticals liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Deciphera Pharmaceuticals -osakkeesta
The business model of Deciphera Pharmaceuticals Inc revolves around developing and commercializing targeted therapeutics for the treatment of cancer. With a primary focus on kinase inhibitors, Deciphera Pharmaceuticals aims to address unmet medical needs and improve patient outcomes. The company prioritizes the discovery and development of small molecule drugs, leveraging its proprietary Kinase Switch Control Inhibitor Platform. By combining innovative science, strategic partnerships, and rigorous clinical research, Deciphera Pharmaceuticals aims to bring transformational therapies to patients living with cancer.
Deciphera Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
Deciphera Pharmaceuticals Inc faces competition from several players in the market. Some of its main competitors include Blueprint Medicines Corporation, Array BioPharma Inc, and Loxo Oncology Inc. These companies are also engaged in the research and development of innovative therapies and treatments in the pharmaceutical industry. However, Deciphera Pharmaceuticals distinguishes itself through its unique approach and expertise in developing highly targeted precision medicine solutions. With its strong pipeline and advancements in kinase inhibitor drugs, Deciphera Pharmaceuticals Inc aims to stand out as a leading player in the market.
Deciphera Pharmaceuticals Inc. is a renowned biopharmaceutical company, known for its innovative approach in developing kinase inhibitor therapies to improve the lives of patients. Founded in 2003 and headquartered in Waltham, Massachusetts, Deciphera has made significant advancements in precision medicine by targeting the underlying causes of cancer and other diseases. With a focus on kinase switch control inhibitors (KSCIs), the company strives to provide effective treatment options for patients with various types of cancers and other serious diseases. Deciphera's dedication to research and development has led to the discovery of multiple potential drug candidates, establishing them as a key player in the pharmaceutical industry.
Deciphera Pharmaceuticals Inc has achieved several significant milestones. The company successfully developed and gained regulatory approval for their lead kinase inhibitor, Qinlock® (ripretinib), to treat advanced gastrointestinal stromal tumors (GIST). Deciphera Pharmaceuticals also obtained accelerated approval from the U.S. FDA for Qinlock® as a fourth-line therapy for GIST patients. Furthermore, they received breakthrough therapy designation from the FDA for Qinlock® in the second-line GIST treatment setting. These milestones highlight Deciphera Pharmaceuticals' commitment to developing innovative treatments for rare cancers and their dedication to advancing patient care.
Deciphera Pharmaceuticals Inc is primarily present in the United States.
Deciphera Pharmaceuticals Inc represents a strong commitment to improving patients' lives through innovative oncology treatments. Guided by a patient-centric approach, the company focuses on personalized medicine that targets specific cancer signaling pathways. Deciphera Pharmaceuticals Inc believes in advancing precision oncology therapies to address unmet medical needs and strives to make a significant impact in the field of cancer research. With their dedicated team and cutting-edge research, Deciphera Pharmaceuticals Inc is devoted to developing transformative therapies that provide hope and enhance the quality of life for patients with cancer.
16 analyytikkoa arvioi tällä hetkellä Deciphera Pharmaceuticals-osaketta: 7 suosittaa ostoa, 9 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Deciphera Pharmaceuticals-yhtiöltä 379,79 M USD liikevaihtoa ja −0,58 USD osakekohtaista tulosta.
Deciphera Pharmaceuticals Analyytikkojen kursstavoitteet 2026
Nykyisellä valuuttakurssilla Deciphera Pharmaceuticals-osake noteerataan hintaan 22,92 EUR (25,59 USD).
Deciphera Pharmaceuticals-osake (DCPH) on listattuna 4 pörssissä, muun muassa: NASDAQ (DCPH), Frankfurt (D05.F), München (D05.MU), Düsseldorf (D05.DU).
Deciphera Pharmaceuticals Inc. is a biopharmaceutical company that develops innovative drugs for the treatment of cancer. The company operates in three main areas: clinical development, research and development, and marketing. The clinical development division focuses on developing drugs for the treatment of cancer. The research and development division specializes in discovering new drugs for cancer treatment. The marketing division works closely with partners to market the company's medical innovations worldwide. The company's goal is to improve the lives of cancer patients and extend their survival through the development and marketing of effective drugs. Overall, Deciphera Pharmaceuticals is committed to improving the lives of cancer patients globally.
odotettu liikevaihto Deciphera Pharmaceuticals on 379,79 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Deciphera Pharmaceuticals on −49,19 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Deciphera Pharmaceuticals:n hinta-voitto-suhde (P/E) on tällä hetkellä −44,22. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Deciphera Pharmaceuticals-osakkeen arvostusta.
Deciphera Pharmaceuticals:n hinta-myynti-suhde (P/S) on tällä hetkellä 5,73. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Deciphera Pharmaceuticals-osakkeen arvostuskennuslukuna.
Deciphera Pharmaceuticals:n Eulpool-laatuscore on 4/10.
Deciphera Pharmaceuticals:n ISIN on US24344T1016. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Deciphera Pharmaceuticals:n WKN on A2H48H. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Deciphera Pharmaceuticals:n ticker on DCPH. Tämä pörssinoteeraus käytetään Deciphera Pharmaceuticals-osakkeiden kauppaan pörssissä.
Deciphera Pharmaceuticals osake
Deciphera Pharmaceuticals vertaisryhmä
Deciphera Pharmaceuticals Ticker
Deciphera Pharmaceuticals FIGI
Kaikki tunnusluvut ja syvällinen analyysi Deciphera Pharmaceuticals:sta
Meidän osakeanalyysimme Deciphera Pharmaceuticals-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Deciphera Pharmaceuticals:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: